Comparing the efficacy of Truvada<sup>® </sup>and Kivexa<sup>® </sup>combination therapy in HAART-naive individuals with different viral loads

25 

Loading....

Loading....

Loading....

Loading....

Loading....

Texto

(1)

All scientific sessions take place in the Clyde Auditorium unless otherwise noted.

SUNDAY 9 NOVEMBER

SS1

11.00–12.30

Satellite Symposium: Pfizer

HAART: Escaping the ‘Red-Queen Effect’. Will new

treatments enable us to win the evolution challenge?

SS1CH

Chairs: Santiago Moreno (Spain)

Mark Nelson (UK)

SS1.1

“Begin at the beginning and go on until you come to

the end. Read the directions and directly you will be

directed in the right direction”

The role of CCR5 antagonists in ART-strategy; when

and how to use them

Jürgen Rockstroh (Germany)

SS1.2

“Curioser and curioser”

Nucleoside sparing regimens: why do we need them?

Graeme Moyle (UK)

SS1.3

“I think I should understand that better . . .”

How important is CD4 count and how to increase it?

Yves Levy (France)

Panel discussion

12.30–13.30

LUNCH

SS2

13.30–15.00

Satellite Symposium: Merck Sharp & Dohme

Reaching new heights in HIV management

SS2CH

Chair: Brian Gazzard (UK)

SS2CH

13.30–13.35

Opening remarks

Brian Gazzard (UK)

SS2.1

13.35–13.55

HIV Treatment Goals: updated guidelines and new

therapeutic opportunities

Brian Gazzard (UK)

SS2.2

13.55–14.20

The evolving role of raltegravir in HIV management

Calvin Cohen (USA)

SS2.3

14.20–14.45

New possibilities in HIV management: real-world

experience

Christine Katlama (France)

14.45–14.55

Panel discussion

SS2CH

14.55–15.00

Closing remarks

Brian Gazzard (UK)

15.00–15.30

COFFEE

SS3

15.30–17.00

Satellite Symposium: GlaxoSmithKline PLC

Pieces of the puzzle – unlocking the potential of

personalised medicine

SS3CH

Chair: Peter Reiss (The Netherlands)

SS3CH

15.30–15.40

Introduction

Peter Reiss (The Netherlands)

SS3.1

15.40–16.00

Translating evidence into practice – efficacy of NRTIs

(2)

SS3.2

16.00–16.20

Personalisation – patients and choices –

understanding safety and long-term treatments

Esteban Martínez (Spain)

16.20–16.30

Questions and answers for Professor Perno and

Professor Martínez

SS3.3

16.30–16.50

A new way of thinking – sharing experiences from

cardiovascular risk in rheumatoid arthritis

George Kitas (UK)

16.50–16.55

Questions and answers for Professor Kitas

SS3CH

16.55–17.00

Closing remarks

Peter Reiss (The Netherlands)

17.00–17.30

COFFEE

17.30–18.00

Official Opening

Ed Byrne, Executive Dean of Biomedicine, Head of

University College London Medical School (UCLMS)

and Vice Provost (Health) (UK)

Brian Williams, President, Royal College of Physicians

and Surgeons of Glasgow (UK)

KL

18.00–19.30

Keynote Lectures

KL1

18.00–18.30

Pathogenesis of HIV infection: implications for

treatment and prevention

Clifford Lane (USA)

KL2

18.30–19.00

How will we use the new ART drugs?

Christine Katlama (France)

KL3

19.00–19.30

The implications beyond public health if we don’t

manage the HIV epidemic

Alan Whiteside (South Africa)

19.30–20.30

WELCOME RECEPTION

MONDAY 10 NOVEMBER

O11

08.30–10.25

Antiretroviral Resistance: What You Want to Know

O11CH

Chairs: Jonathan Schapiro (Israel)

Anders Sönnerborg (Sweden)

O111

08.30–08.50

Global impact of HIV drug resistance

Deenan Pillay (UK)

O112

08.50–09.05

Trends in transmitted HIV drug resistance among

non-B subtypes in the UK

Daniella Chilton (UK)

O113

09.05–09.20

HIV-1 clade C resistance genotypes after first

virological failure in a large community ART

programme

Catherine Orrell (South Africa)

O114

09.20–09.35

NNRTI mutations are efficiently transmitted within

clusters of new HIV infections

(3)

SCIENTIFIC PROGRAMME (continued)

O115

09.35–09.55

Importance of detecting minority variants in the

clinical management of HIV

Dan Kuritzkes (USA)

09.55–10.25

Panel discussion and questions

10.25–10.55

COFFEE

O12

10.55–12.40

Essential Pharmacology

O12CH

Chairs: David Back (UK)

Janet Darbyshire (UK)

O121

10.55–11.10

Prevalence of drug interactions between

antiretroviral and co-administered drugs at the MOI

teaching and referral hospital (Ampath), Eldoret,

Kenya

Saye Khoo (UK)

O122

11.10–11.25

To overdose or underdose? The question of Kaletra

in children in the UK/Irish Collaborative HIV

Paediatric Study (CHIPS)

Sarah Walker (UK)

O123

11.25–11.45

Drug interactions that really matter

Saye Khoo (UK)

O124

11.45–12.00

Efavirenz and rifampicin in the South African context:

is there a need to dose increase efavirenz with

concurrent rifampicin therapy?

Catherine Orrell (South Africa)

O125

12.00–12.15

Impact of efavirenz and nevirapine on

pharmacokinetics of lopinavir/ritonavir as tablets and

capsules in African patients

Cissy Kityo (Uganda)

12.15–12.40

Panel discussion

12.40–14.10

LUNCH AND POSTERS

(including Poster Discussion Sessions)

Hall 4, Room 1

13.00–14.00

Treatment Strategies: Naïve Patients

PCH

Chairs: Brian Gazzard (UK)

Alain Volny-Anne (France)

P1

Clinical effect of interleukin-2 (IL-2) immuno-adjuvant

treatment in HIV+ advanced naïve patients

Camilla Tincati (Italy)

P2

Efficacy and safety of TMC278 in treatment-naïve,

HIV-infected patients: week 96 data from

TMC278-C204

Katia Boven (USA)

P3

Impact of antiretroviral dosing and daily pill burden

on viral rebound rates in naïve patients receiving a

tenofovir-based regimen

Andrea Antinori (Italy)

P53

Efficacy and safety of switching from lopinavir/r to

atazanavir/r in suppressed patients receiving a

LPV/r-containing HAART: ATAZIP 96-week results

(4)

P54

48-week outcomes following switch from AZT/3TC

to FTC/TDF (TVD) vs. continuing on AZT/3TC:

48-week interim analysis of the RECOMB trial

Esteban Ribera (Spain)

P306

NRTI backbone pairs for treatment-naïve adults with

HIV infection: a UK economic evaluation

Edward Hutt (USA)

Hall 4, Room 2

13.00–14.00

Strategies for the Experienced: Immunology and

Inflammation, the Lung, and Sex

PCH

Chairs: Judith Currier (USA)

Simone Marcotullio (Italy)

P61

Simplification of therapy (ART) with efavirenz/

emtricitabine/tenofovir DF single tablet regimen vs.

continued ART in suppressed, HIV-infected patients

Ben Young (USA)

P167

Effect of a fixed-dose combination of emtricitabine,

tenofovir and efavirenz on adherence and treatment

acceptability (ADONE study)

Franco Maggiolo (Italy)

P70

Evolution of CD4+ T-cell count in HIV-1 infected

adults receiving antiretroviral therapy with sustained

long-term virological suppression

Helen Byakwaga (Australia)

P297

Changes in CCR5+ cells and antigen-specific

CD4+ T-cells during monotherapy with a CCR5

antagonist SCH532706 compared with combination

therapy

Sarah Pett (Australia)

P213

D-dimer and anti-coagulation activity markers in

children and adolescents with HIV infection

Giuseppe Pontrelli (Italy)

P299

What about primary pulmonary hypertension in HIV

infection in the era of combination antiretroviral

therapy?

Murielle Mary-Krause (France)

P71

Virological treatment outcome under HAART: does

sex matter?

Annette Haberl (Denmark)

14.10–14.20

The HIV Research Trust: Report on Progress

Robert Souhami, Chairperson of the HIV Research

Trust (UK)

O13

14.20–16.30

Headlines from Resource-poor Settings

IAS Session

O13CH

Chairs: Pedro Cahn (Argentina)

Ade Fakoya (International AIDS Alliance, and UK)

O131

14.20–14.40

Where are we with National and International

guidelines?

Elly Katabira (Uganda)

(5)

O133

15.00–15.20

HIV/TB: when is it safe to start HAART?

Robin Wood (South Africa)

O134

15.20–15.40

HIV disease management and challenges in Eastern

Europe and Central Asia

Alexey Bobrik (Russian Federation)

O135

15.40–16.00

Seek and treat for optimal prevention of HIV/AIDS

(STOP HIV/AIDS)

Julio Montaner (Canada)

16.00–16.30

Panel discussion

16.30–17.00

COFFEE

SS4

17.00–18.30

Satellite Symposium: Boehringer Ingelheim GmbH

Aiming for the long-term: focus on the individual

SS4CH

Chair: José Gatell (Spain)

SS4CH

17.00–17.05

Welcome and introduction

José Gatell (Spain)

SS4.1

17.05–17.25

Considering the individual – principles of treatment

choice

Laura Waters (UK)

SS4.2

17.25–17.50

Initiating and maintaining HAART – aiming for the

long term in treatment-naïve patients

Georg Behrens (Germany)

SS4.3

17.50–18.20

Understanding PI resistance – aiming for the long

term in treatment-experienced patients

Anna Maria Geretti (UK)

18.20–18.30

Panel discussion

TUESDAY 11 NOVEMBER

O21

08.30–09.50

The CNS, Immune Response and Treatment

Interruption Revisited

O21CH

Chairs: Margaret Johnson (UK)

Stefano Vella (Italy)

O211

08.30–08.50

HIV and the brain: neuro-inflammation long-term,

CNS control of HIV replication, brain disease in

suppressed patients and differential penetration

of drugs

David Clifford (USA)

O212

08.50–09.05

Rate of change in CD4 counts in patients with stable

HIV viraemia

Amanda Mocroft (UK)

O213

09.05–09.20

CD4–guided STI in patients responding to HAART

Franco Maggiolo (Italy)

O214

09.20–09.35

The FOTO study: 24-week results support the safety

of a 2-day break on efavirenz-based antiretroviral

therapy

Calvin Cohen (USA)

09.35–09.50

Panel discussion

09.50–10.20

COFFEE

(6)

O22

10.20–12.15

Children: From Birth to Longevity

O22CH

Chairs: Hermione Lyall (UK)

Ian Weller (UK)

O221

10.20–10.35

Antiretroviral Pregnancy Registry (APR) at 10,000

prospective reports

Karen Beckerman (USA)

O222

10.35–10.50

Treatment interruption in children with chronic

HIV-infection: the results of the paediatric European

network for treatment of AIDS (PENTA) 11 trial

Di Gibb (UK)

O223

10.50–11.10

Optimising paediatric treatment for long-term

survival. Adult survivors of congenital HIV infection:

what problems will they have?

Hermione Lyall (UK)

11.10–11.25

Panel discussion

O224

11.25 –12.15

Special Guest Lecture

The early AIDS Epidemic in the US: views from

Atlanta and Hollywood

Harold Jaffe (UK)

12.15–13.45

LUNCH AND POSTERS

(including Poster Discussion Sessions)

CoS

12.25–13.45

Community Session

Lomond Auditorium

Can HAART Prevent HIV Transmission?

CoSCH

Chairs: Sean Hosein (Canada)

Alain Volny-Anne (France)

Earlier this year the Swiss Federal AIDS Commission

published a paper stating that having an undetectable

viral load made HIV positive people non-infectious.

This position paper has incited intense controversy,

being published against a background of increasing

criminalisation of HIV transmission, difficulty of

disclosure, and the psychological burden of living with

a stigmatised and chronic illness.

The internationally renowned panel members will each

make a 10-minute presentation on their perspective that

will serve as a foundation for the insightful and spirited

discussion that will follow.

CoS.1

Bernard Hirschel (Switzerland)

CoS.2

Cate Hankins (Switzerland)

CoS.3

Paul MacPherson (Canada)

(7)

SCIENTIFIC PROGRAMME (continued)

Hall 4, Room 1

12.30–13.30

Adverse Events

PCH

Chairs: Simon Mallal (Australia)

Fiona Mulcahy (Ireland)

P128

Kidney tubular abnormalities in HIV patients treated

with tenofovir with normal glomerular function:

results of a prospective study on 284 patients

Pablo Labarga (Spain)

P150

Frequency of bone abnormalities and associated

factors in a Spanish cohort of HIV-infected patients

Anna Bonjoch (Spain)

P234

Improvement of atazanavir-induced

hyperbilirubinaemia following TDM-guided atazanavir

dose reduction

Massimo Giola (Italy)

P288

Predictors of immune reconstitution inflammatory

syndrome associated with Kaposi sarcoma (IRIS-KS)

in a rural area of Mozambique

Emilio Letang (Spain)

P289

Impact of HIV treatment on clearance of human

papillomavirus (HPV) infection in HIV-infected

women

Deborah Konopnicki (Belgium)

Hall 4, Room 2

12.30–13.30

Treatment Strategies: Experienced Patients

PCH

Chairs: Andrzej Horban (Poland)

Andrew Phillips (UK)

P20

Raltegravir: a potent and safe integrase inhibitor

with a favourable impact on cardiovascular and

liver profile

Francisco Blanco (Spain)

P21

POWER 1 and 2: combined final 144-week efficacy

and safety results for darunavir/ritonavir (DRV/r)

600/100 mg BID in treatment-experienced HIV

patients

Christine Katlama (France)

P22

Phase III TITAN week 96 final analysis: efficacy/

safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r)

in LPV-naïve, treatment-experienced patients

Christine Katlama (France)

P23

Virological response with fully active etravirine (ETR;

TMC125) after 48 weeks of treatment: pooled results

from the DUET-1 and DUET-2 trials

Nathan Clumeck (Belgium)

O23

13.45–15.00

Hepatic Headlines

O23CH

Chairs: Antonella d’Arminio Monforte (Italy)

Stephen Storfer (USA)

O231

13.45–14.00

Cryptogenic liver disease, steatosis, portal

hypertension, transaminitis and antiretrovirals

(8)

O232

14.00–14.15

What’s new in hepatitis C?

Vincent Soriano (Spain)

O233

14.15–14.30

Surrogate markers for liver damage: how can we

measure the extent of fibrosis and disease without

biopsy?

Massimo Puoti (Italy)

14.30–15.00

Panel discussion

CS1

15.00–16.30

Assessment of the Sick HIV-positive Returning

Traveller: Case Studies Session held in collaboration

with European AIDS Clinical Society

CS1CH

Chairs: Manuel Battegay (Switzerland)

Peter Reiss (The Netherlands)

Panel: Nathan Clumeck (Belgium)

Bob Colebunders (Belgium)

John Gill (Canada)

Alison Grant (UK)

Roy Gulick (USA)

Christoph Hatz (Switzerland)

15.20–16.10

Cases

CS1.1

Traveller going to tropical region

Aisling Loy (Ireland)

CS1.2

Immigrant arriving from sub-Saharan Africa

Michele van Vugt (The Netherlands)

CS1.3

Traveller returning with diarrhoea

Emilio Letang (Spain)

CS1.4

Traveller returning with fever

Yves van Laethem (Belgium)

CS1.5

16.10–16.30

Mini-review: Important issues considering sick

HIV-positive returning traveller or immigrant from

a tropical region

Christoph Hatz (Switzerland)

16.30–17.00

COFFEE

SS5

17.00–18.30

Satellite Symposium: Bristol-Myers Squibb

The burden of choice

SS5CH

Chair: Jürgen Rockstroh (Germany)

SS5CH

17.00–17.10

Introduction

Jürgen Rockstroh (Germany)

SS5.1

17.10–17.35

Why NNRTIs should be the standard in treatment

initiation

Mark Nelson (UK)

SS5.2

17.35–18.00

Why PIs should be the standard in treatment

initiation

Calvin Cohen (USA)

18.00–18.20

Interactive discussion session

Calvin Cohen, Mark Nelson and Jürgen Rockstroh

SS5.3

18.20–18.30

Is choice still a burden? Keep it simple!

Jürgen Rockstroh (Germany)

(9)

SCIENTIFIC PROGRAMME (continued)

ES1

18.30–20.00

Evening Symposium: Abbott

Lomond

Clinical dialogues: Face-to-face with today’s practice

Auditorium

challenges

ES1CH

Chair: Ed Wilkins (UK)

ES1CH

18.30–18.35

Welcome

Ed Wilkins (UK)

ES1.1

18.35–18.55

Flexible treatment regimens: A prelude to improved

outcomes?

François Raffi (France)

ES1.2

18.55–19.15

Case study dialogue: Addressing the complexities of

long-term ARV treatment

François Raffi (France)

Panel discussion

Moderated by Ed Wilkins (UK), joined by

Bruno Spire (France), François Raffi (France) and

Pere Domingo (Spain)

ES1.3

19.15–19.35

Lipoatrophy: Untangling the differences among ARVs

Pere Domingo (Spain)

ES1.4

19.35–19.55

Case study dialogue: Reflecting on lipoatrophy and

body fat changes

Ed Wilkins (UK)

Panel discussion

Moderated by Ed Wilkins (UK), joined by

Bruno Spire (France), François Raffi (France) and

Pere Domingo (Spain)

ES1CH

19.55–20.00

Summary and close

Ed Wilkins (UK)

ES2

18.30–20.00

Evening Symposium: Tibotec, a division of

Hall 2

Janssen-Cilag Ltd

Spanning the treatment spectrum for HIV-1-infected

patients: A new era?

ES2CH

Chair: Anton Pozniak (UK)

ES2CH

18.30–18.35

Welcome and introduction

Anton Pozniak (UK)

ES2.1

18.35–18.50

A new era in the management of HIV-infected

patients

Bernard Hirschel (Switzerland)

ES2.2

18.50–19.10

Optimising treatment outcomes for

treatment-experienced patients

Giovanni Di Perri (Italy)

ES2.3

19.10–19.30

Providing treatment-naïve HIV-1-infected patients

with optimal care

Hans-Jürgen Stellbrink (Germany)

ES2.4

19.30–19.45

Looking to the future: expanding opportunities

across the treatment spectrum

Christine Katlama (France)

19.45–20.00

Panel discussion

ES2CH

20.00

Closing remarks

(10)

WEDNESDAY 12 NOVEMBER

O31

08.30–10.10

‘Non-AIDS Morbidities’: Part of Life, HIV Disease

and/or Adverse Events of Therapy

O31CH

Chairs: David Cooper (Australia)

Ray Fox (UK)

O311

08.30–08.50

Pathogenesis of non-AIDS morbidities in HIV disease

and implications for management

Steven Deeks (USA)

O312

08.50–09.10

Cardiovascular disease; HIV, ART, immunodeficiency,

pro-inflammation and other factors

Jens Lundgren (Denmark)

O313

09.10–09.25

Relation between adverse effects of ARV treatment

and underlying risk in number needed to treat

to harm (NNTH): myocardial infarction and

abacavir use

Justyna Kowalska (Denmark)

O314

09.25-09.40

Predicting the short-term risk of diabetes in

HIV-infected patients in the D:A:D cohort: the D:A:D

study group

Kathy Petoumenos (Australia)

09.40–10.10

Panel discussion

10.10–10.40

COFFEE

O32

10.40–12.15

Cancer, Bone and Renal Disease

O32CH

Chairs: William Powderly (Ireland)

Rainer Weber (Switzerland)

O321

10.40–11.00

HIV, immune deficiency and malignancy

Andrew Grulich (Australia)

O322

11.00–11.20

Bone disease and HIV: together for the long term

Patrick Mallon (Ireland)

O323

11.20–11.35

High HIV viral load inhibits osteoblast function and

signalling

Nicholas Chew (Ireland)

O324

11.35–11.55

Management of renal disease in HIV infection for the

HIV physician

Ian Williams (UK)

11.55–12.15

Panel discussion

12.15–13.45

LUNCH AND POSTERS

(including Poster Discussion Sessions)

Hall 4, Room 1

12.30–13.30

HIV-related Infections, Co-infections and Cancers:

Hepatitis Co-infection (HCV and HBV)

PCH

Chairs: NM Samuel (India)

Mauro Schechter (Brazil)

P134

Risk factors for end-stage liver disease among HIV

and hepatitis C virus co-infected patients in the

Spanish VACH Cohort

(11)

SCIENTIFIC PROGRAMME (continued)

P135

Screening for liver fibrosis in HIV-mono-infected

patients with increased ALT comparing FibroScan

with FIB-4

Stefan Mauss (Denmark)

P264

Cross-sectional study to determine prevalence of

significant liver fibrosis (F2-F4) in HIV/HCV

co-infected patients: GRAFIHCO study

Angel Burgos (Spain)

P265

A 4-year follow-up of a cohort of HIV-positive

cirrhotic patients

Paula Tuma (Spain)

P266

Rapid virological response is the best predictor for

achieving SVR under peg-IFN/ribavirin hepatitis C

therapy in HIV/HCV co-infected patients

Jürgen Rockstroh (Germany)

P267

Switching from zidovudine/lamivudine (ZDV/LMV) to

tenofovir/emtricitabine (TDF/FTC) or abacavir/

lamivudine (ABC/LMV) in HIV/HCV co-infection

(COTKI study)

Paola Nasta (Italy)

P268

HCV relapse after peg-interferon (IFN) plus ribavirin

(RBV) therapy: is 12-week follow-up enough to

determine sustained HCV clearance?

Jose Medrano (Spain)

Hall 4, Room 1

12.30–13.30

Laboratory Monitoring of Disease and Therapy

PCH

Chairs: Saye Khoo (UK)

Veronica Miller (USA)

P178

Re-evaluation of resistance algorithms for

lopinavir/ritonavir in the TITAN trial

Vincent Calvez (France)

P197

Validation of an enhanced sensitivity Trofile™ HIV-1

co-receptor tropism assay for selecting patients for

therapy with entry inhibitors targeting CCR5

Jacqueline Reeves (USA)

P198

Prevalence of CCR5-tropic HIV-1 among

treatment-experienced individuals in South Africa infected with

Clade C virus

Sybil Eng (USA)

P199

Therapeutic drug monitoring of new formulation

Kaletra in pregnancy

Laura Else (UK)

P241

Modelling the change in lopinavir apparent oral

clearance over time following cessation of

lopinavir/ritonavir: data from the TAIL study

(12)

O33

13.45–15.00

Important Recent Findings from Cohort Studies

O33CH

Chairs: Cristina Mussini (Italy)

Jeff Nadler (USA)

O331

13.45–14.00

Patterns of viral suppression on cART as predictors

of uncontrolled viraemia after starting a new

antiretroviral after 1 January 2003

Joanne Reekie (UK)

O332

14.00–14.15

Opportunistic infections in immunocompromised but

virologically suppressed HIV-1 infected patients

Wendy Bannister (UK)

O333

14.15–14.30

Treatment discontinuation and virological failure

amongst HIV-positive individuals starting second-line

combination antiretroviral therapy (cART)

Colette Smith (UK)

14.30–15.00

Panel discussion

CS2

15.00–16.30

Update on the Clinical Management of Complex

HIV/AIDS Cases: Interactive Session held in

collaboration with IAS-USA

CS2CH

Chairs: Roy Gulick (USA)

Ian Williams (UK)

Panel: Judith Currier (USA)

Cristina Mussini (Italy)

Cases

CS2.1

Strategies for antiretroviral therapy

Roy Gulick (USA)

CS2.2

Co-morbidities and complications that impact

antiretroviral decisions

Ian Williams (UK)

CS2.3

Current issues in viral hepatitis co-infection with

HIV

Jürgen Rockstroh (Germany)

16.30–17.00

COFFEE

SS6

17.00–18.30

Satellite Symposium: Gilead Sciences Europe Ltd

Understanding and overcoming the challenges of late

presentation of HIV patients

SS6CH

Chair: Jürgen Rockstroh (Germany)

SS6CH

17.00–17.10

Welcome

Jürgen Rockstroh (Germany)

SS6.1

17.10–17.30

The epidemiology of late presentation in HIV

Caroline Sabin (UK)

SS6.2

17.30–17.45

Strategies to encourage earlier presentation and

diagnosis: The European experience

Antonio Antela (Spain)

SS6.3

17.45–18.00

Strategies to encourage earlier presentation and

diagnosis: The US experience

Yvette Calderon (USA)

(13)

SCIENTIFIC PROGRAMME (continued)

SS6CH

18.20-18.30

Summary and close

Jürgen Rockstroh (Germany)

18.30–20.00

POSTER RECEPTION

THURSDAY 13 NOVEMBER

O41

08.30–10.00

Hot Topics and Late Breakers 1

O41CH

Chairs: Eric Sandström (Switzerland)

Schlomo Staszewski (Germany)

O411

08.30–08.50

HIV–TB co-infection and TB drug resistance: an

emerging threat to HIV and TB programmes

Gerald Friedland (USA)

O412

08.50–09.05

Factors associated with poor clinical outcome among

HIV-infected patients with TB in Europe and

Argentina. The HIV/TB collaborative study

Daria Podlekareva (Denmark)

O413

09.05–09.20

Pharmacokinetics of once-daily etravirine without

and with once-daily darunavir/ritonavir in

antiretroviral-naïve HIV-1 infected adults

Thomas Kakuda (USA)

O414

09.20–09.35

48-week data from Study AVX-201: a randomised

phase IIb study of apricitabine in

treatment-experienced patients with M184V and NRTI

resistance

Susan Cox (Australia)

O415

09.35–09.50

Efficacy and safety of 48-week maintenance with QD

ATV vs. ATV/r (both + 2NRTIs) in patients with VL

<50 c/mL after induction with ATV/r + 2NRTIs:

Study AI424136

Santiago Moreno (Spain)

09.50–10.00

Panel discussion

10.00–10.30

COFFEE

O42

10.30–12.05

Hot Topics and Late Breakers 2

O42CH

Chairs: José Gatell (Spain)

Ian Weller (UK)

O421

10.30–10.50

When to start therapy? The patient’s viewpoint

Gus Cairns (UK)

O422

10.50–11.05

Do the disadvantages of late initiation of HAART

persist in patients achieving and maintaining viral load

suppression for a year on HAART?

Laura Waters (UK)

O423

11.05–11.20

Risk of new AIDS-defining events in patients with

advanced immunodeficiency during suppressive

HAART: results from the German ClinSurv cohort

Alexander Zoufaly (Germany)

O424

11.20–11.35

Resistance development in virological failures with

DRV/r or LPV/r: 96-week analysis of the Phase III

TITAN trial in treatment-experienced patients

(14)

O425

11.35–11.50

Efficacy and safety of maraviroc in

treatment-experienced patients infected with R5 HIV-1:

96-week combined analysis of MOTIVATE 1 and

2 studies

David Hardy (USA)

11.50–12.05

Panel discussion

12.05–12.15

Closing Remarks

12.05–12.10

Closing comments from the EATG representative

Wim Vandevelde (Portugal)

12.10–12.15

Closing comments from the Congress Chairperson

Ian Weller (UK)

12.15–13.00

LUNCH AND CLOSE OF CONGRESS

KEYNOTE LECTURERS

We are delighted to have secured contributions from the following internationally renowned

individuals and hope that the information below will be of interest in relation to the Keynote

Lecture session on Sunday evening following the Official Opening.

Christine Katlama has worked in the field of HIV since 1982 and was

involved in the discovery of HIV-2 in 1986. Her group first demonstrated

the impact of HAART on immune reconstitution and works extensively in

the field of new drugs and resistance.

Professor Katlama is a founder member of ORVACS, which is developing

a therapeutic vaccination programme for HIV-infected patients. As a

founder and President of Solthis (Solidarité Thérapeutique & Initiatives

Contre Le SIDA), a non-governmental organisation, she is also heavily

involved in access to HIV treatment and education in developing

countries.

Professor Katlama was President of the European AIDS Clinical Society until July 2004, and remains

an active member, involved in many educational initiatives. She is a member of the editorial boards

of several journals, including

HIV Medicine

and

AIDS

.

(15)

AUTHOR INDEX

Aarons, L P241 Abad, F P162 Abdalla Elteer, A P214 Abdel-Kader, L P141 Abdon, A P78 Abrescia, N P3 Absalon, J P8, P136* Abu Bakar, M P305* Acinapura, R P166 Ackad, N P81 Adesola, O P172 Adeyemi, A P172* Adorni, F P34 Adorni, FA P194 Aggett, S P229* Agostinone, A P152 Agud Aparicio, J P93, P100,

P173 Aguirrebengoa, K P33 Ahmed, N P227 Ahmed, S P79 Aich, B P193 Airoldi, M O213, P167 Álamo del Rodríguez, M P93 Alas, B P68 Albalate, M P128 Alcalde-Encinas, M P164, P254 Alcarez, C P33 Alcorn, K O421 Alessandra M. Martino, A P214 Ali S. Bengleil, A P214 Allavena, C P26* Allegri, G P313 Almasi, F P46*, P287* Almeida, I P51 Almeida, J P288 Aloisi, M P177 Alonso, P P288 Altclas, J O414 Alterio, L P152 Altice, F P240 Álvarez, Á P89 Álvarez, M P54, P78 Ambar, R P196, P209 A-Megido, J P290 Amiramini, S P212 Ammari IME P214 Ammassari, A P3, P166 Amoroso, A P121 An der Heiden, M O423 Ancock, B P116* Andersen, T P90 Anderson, J O422, P73*, P203 Andrade, M P89 Andreoni, M P3, P56 Andrews, L P240 Angeletti, G P118 Anghel, N P257 Antela, A SS6.2, P44

Antinori, A P3*, P166, P169, P179, P292 Antinori, S P274 Antoniadou, A P186, P294 Antonopoulou, S P105 Apostolova, N P120, P161* Aquilina, C P29 Arama, V P255 Arastéh, K P24 Arazo, P P64 Arbune, M P261* Arechavala, A P252 Arildsen, H P90 Arranz, J P53 Arredondo, M P20 Arribas, J P44, P64, P308 Arumainayagam, J P15 Asghar, A P248* Ashby, J P260 Aster, V P295* Avidor, B P188 Avihingsanon, A P244* Awni, W P95, P101, P245, P247 Awunor, C P149 Ayala, E P288 Ayoub, A P154* Azijn, H P181, P189

Babu, C P79 Back, D O121, O12CH, P6,

P233, P237, P238, P250 Badal-Faesen, S P198 Bai, F P1, P88, P97, P167 Baietto, L P233 Bailey, A P260, P262* Bailey, M P297 Baily, G P203 Bakoyiannis, G P124 Balcarek, K P147 Baldelli, F P10, P84, P118 Balestra, P P292 Balle, N P174 Ballesteros, D P120, P161 Ballestri, S P139, P140 Balogh, A O415 Bambumba, A P79 Bandivdekar, A P211 Bánhegyi, D P22 Bannister, W O332* Barassi, A P235 Barda, B P202 Barker, R P262 Barlow, P P289 Barranger, E P222 Barreiro, P P128, P137, P138,

P265, P268, P284, P286 Barrieshee, A P278* Barrios, A P173, P251

Barros, C P173 Barrufet, P P92 Basilico, C P234 Bassaris, H P124 Bastos, R P288 Battegay, M CS1CH Batuca, J P96 Baumgardt, C P32 Baumgarten, A P7, P75 Baxter, J P190, P192* Beauvoit, B P147, P148 Becker, E P304* Beckerman, K O221* Bedimo, R P9* Beets, G P23, P27 Beghetto, B P115, P156, P300 Behrens, G SS4.2 Beijnen, J P242 Belaebi, L P46 Belda, A P162 Bele, V P193 Belfiori, B P84 Bellagamba, R P292 Bellido, R P142 Bellistrì, G P1, P88, P97 Bellos, N P21 Benea, O P255, P261 Benetucci, J P252 Bengleil, AS P214 Beniowski, M O331 Berenguer, J P54 Berg, J P315 Berg, T P201 Berger, F P135, P160 Bergin, C P132, P155, P276,

P293 Bergman, J P222 Bernardi, S P213 Bernasconi De Luca, D P234 Bernstein, B P95, P101, P110,

P245, P247 Berry, A P249 Bertheau, P P269 Bhatti, L P190, P192 Biagetti, C P123 Bickel, M P18*, P32, P59*,

P122 Bigoloni, A P45 Bijuklic, K P200 Billing, N P98* Bini, T O213, P88, P153, P167,

P235 Bino, S P87 Biondi, M P235 Bisi, L P167, P273 Bisicchia, F P17 Bisimba, J P175* Bissé, E P210 Bissio, E P317*

Name Activity Name Activity Name Activity

(16)

Blanc, C P38 Blanco, F P20*, P42, P66, P128, P137* Blanco, JL P64 Blanco JR P64 Blas-García, A P120*, P161 Blaxhult, A P82 Bobrik, A O134* Bodtlaender, A P59 Boffito, M P241 Bogner, J O212 Bolan, R P303 Bonfanti, P P19, P74 Bonjoch, A P50*, P150* Bonnet, J P147, P148 Bonora, S P233 Boorman, H P28 Boothby, M P113* Borderi, M P123* Borghi, V P273* Borras-Blasco, J P162* Boschi, A P30 Bossola, M P177 Bottecchia, M P284 Bottieau, E P270, P283* Bouzas, M P252 Bovee, I P208 Boven, K P2*, P239 Bower, M P14, P49, P116, P248 Boyce, C P121 Boyd, K O122 Boyd, M P70 Boyle, N P199 Bracciale, L P168 Bradbeer, C P305 Branco, T P96, P155 Brandolini, M P56 Braun, P P12, P43, P201 Bravenboer, B P55 Bravo, I P65 Bray, D P206 Breiden, J P246 Brennan, M P199, P246 Brenner, B O114 Brodt, H P32 Brogan, A P306, P309 Brosa, M P314 Bruce, R P240* Brun, F P92 Bruyand, M O314, O412 Buelens, A P239 Burapat, C P259 Burger, D P244 Burgos, A P80, P117, P264*,

P308 Burk, M P188 Butler, K O122 Buvé, A P223

Buxton, G P107* Buzon, M P50 Byakwaga, H P70*

Caballero, E P40 Cabie, A P26 Cabrero, E P80, P117, P264, P308 Caffagni, G P140 Cahn, P O414 , O13CH Cain, K P259 Cairns, G O421* Cairns, V P41 Caixas, U P96 Calbi, M P99 Calcagno, A P233 Caldas, C P296* Calderon, Y SS6.3 Callegaro, A O213 Caluwaerts, S P223 Calvez, V P29, P178* Calza, L P165 Camacho, R P51 Camanni, G P10, P118* Cambrea, S P226* Campbell, L P260* Candido, V P196 Canestri, A P38* Cañizal, A P252 Cano-Sánchez, A P164, P254 Capasso, M P39 Capetti, A P31* Caramma, I P274 Carcaba, V P290 Cardellach, F P142, P143, P144, P146 Cardoso, S P296 Carganico, A P13, P25 Carini, E P45 Carlebach, A P18 Carocci, C P69* Carosi, G O415, P52, P267,

P282 Carradori, S P74 Carrilho, C P288 Casado, J P80* Casana, M P88, P97, P153*,

P235* Casas, E P65, P173 Caseiro, M P196, P209 Casillas Rodriguez, J P104, P108 Cassetti, I O414, P4 Castagna, A P36, P37, P45, P202 Castaño, M P141 Castera, M P162 Castilla, V P251 Castro, A P42, P92

Castro Lopez, H P104*, P108* Cattelan, A P56 Cauda, R P99, P243 Caum, C P150 Caumes, E P269 Cavassini, M P231 Caylá, J O412 Ceccherini-Silberstein, C P35,

P179 Cecchini, D P252* Celesia, B P17* Cervero, M P173* Cervero Jiménez, M P93*,

P100* Cesari, M P1, P274 Chadwick, D P107 Chaikan, A P237* Chandramani, S P15 Chanmano, S P244 Charles, M P229 Charlotte, F P269 Chaudhary, M P310 Chauret, N P298 Chein, M P303 Cheng, A P4 Chernai, N P222 Chew, N O323*, P109* Chiavaroli, R P106, P131 Chierakul, N P237 Chiesa, E P206 Chiesi, A O331 Chilton, D O112* Chini, M P47, P105 Chiodo, F P123 Chiotan, C P255 Chirianni, A P3 Chiu, Y P95 Chranioti, K P294 Christensen, J P90 Christie, A P315 Chuah, J P72 Chuchuttaworn, C P237 Chui, Y P245, P247 Cicconi, P P153, P235 Cingolani, A P168 Ciraru-Vigneron, N P222* Citton, R P213 Clark, D P203* Clay, E P303 Clerici, M P206 Clermont, P P298 Clifford, D O211* Clotet, B O331, P23, P33, P42,

P50, P54, P58, P64, P65, P67, P114, P142, P150, P157, P171, P176, P191, P272* Clumeck, N P23*, P48, P289 Coakley, E P190, P197 Cobos-Trigueros, N P164, P254

(17)

AUTHOR INDEX (continued)

Coelho, R P296 Coen, M P206 Cohen, C O214*, SS2.2, SS5.2,

P157 Cohen, D P110, P170 Cohen, K O124 Colafigli, M P243 Colberg, K P62 Colby, D P77 Colebunders, R P228, P270 Cologni, G P52, P282 Colson, A O214 Comi, L P88, P97, P153, P235 Compagnucci, A O222 Compangocci, A P46 Comparini, R P209 Conner, C P121, P240 Contés, E P251 Conway, B P81*, P277*, P278 Cooper, C P28 Cooper, D O414, O31CH, P70,

P244, P297 Cordes, C P2 Córdoba, M P20 Coria Ramirez, E P108 Corpolongo, A P3 Corsi, C P69 Corso, N P133 Cortés, C P92 Cosín, J P53, P78, P134 Cossarini, F P202 Costagliola, D P299 Costarelli, S P52 Cotter, E O323 Coulter-Smith, S P199, P246 Couto-Parada, X P203 Covington, D O221 Cox, S O414* Cozzi-Lepri, A P183 Crauwels, H P239* Crespo, M P40 Cristina, M P88 Cui, Y P247 Cuko, G P153 Cupsa, A P257 Curran, A P40, P54 Currier, J PCH Curtin, J P57 Cusato, M P234 Cuthbertson, Z P6, P250 Cuzin, L P26

Da Cunha, C P22 Da Silva, B P95, P101*, P110*,

P245 Daikos, G P186 D’Alessandro, M P19 D’Amico, R P125, P139, P140

Daniels, R P14* d’Aquin Toni, T O114 Darbyshire, J O12CH d’Arminio Monforte, A O314,

O332, O23CH, P1, P88, P97, P153, P235 D’Arrigo, R P35, P179 Das, A P28 Das, S P15*, P113 Däumer, M P201 Davies, A P91 Davies, G P237 Davis, C P121* D’Avolio, A P233 de Barra, E P132, P293 de Béthune, M O424, P189 De Boer, M P283 de Gaetano Donati, K P99* De Gennaro, M P206 de Guzmán, M P251 de la Calle, O P314 De la Torre, J P65, P112 de Lazzari, E P53 De Longis, P P169 De Luca, A P99, P168, P243 De Meyer, S O424*, P21, P24,

P181, P189 De Pablo-Bernal, C P89 De Paepe, E O424 De Silvestri, A P30 De Smedt, G P23, P27, P189,

P272 De Socio, G P19, P74 De Terlizzi, F P215 De Wit, S O314, P36, P37, P48*, P289 De Wolf, H P205 Deeks, S O311* Degen, O P62* Deig, E P78, P146 DeJesus, E O214, O413, P61,

P63 del Álamo Rodríguez, M P100 del Arco, A P102 Delforge, M P48, P289 Delfraissy, J O415 Delgado, C P51 Delgado-Alves, J P96 Della Torre, L P202 Dellamonica, P P26 Deloof, A P205* Delpech, V O112 Demeester, R P283 Demopoulos, C P105 Deshpande, A P211 Deveaud, C P147, P148 DeWet, J P81 Di Biagio, A P215 Di Castelnuovo, A P99

Di Giambenedetto, S P168, P243 Di Masi, F P152 Di Matteo, L P152 Di Perri, G ES2.2, P233 Di Vincenzo, P P39, P194 Diaz, M P40 Diaz, R P209 Dickinson, L P237, P241* Diderichsen, P P245 Dierynck, I O424, P189 Dietz, B P307, P311, P312 Diniz, A P51 Doan, T P95, P101 Dobosz, S P216*, P217 Doerholt, K O122 Dolara, A O213 Domingo, P ES1.3, P42, P53,

P67, P134, P191 Dominguez, K O221 Doran, P O323 Dragsted, U P6, P250 Dravid, A P193 Drechsler, H P9 Duarte, N P196 Dufty, N P249 Duiculescu, D P224, P275* Dumitrescu, F P257* Duncan, A P204 Duncan, F P277 Dunlop, W P310* Duvivier, C P26

Eberhard, A P195 Eberle, J P200 Eberle, S P86 Ebrahimi, R P61, P63 Eccleston, K P79* Echeverría, P P53, P65*, P67*,

P150 Edwards, C P91 Edwards, I O121 Egle, A P200 Egnell, K P256 Ehret, R P43 ELA Group*, P65 Elbasha, E P310 Elion, R O214 Ellis, E P219, P225 El-Sadr, W O314 Else, L P6, P199, P241, P246,

P250* Elteer A P214 Emery, S P70, P297 Emmelkamp, J P266, P304 Ene, L P275 Enejosa, J P4 Eng, S P198* England, K P218*

Name Activity Name Activity Name Activity

(18)

English, S P103* Epting, T P210 Eron, J P27 Esplugues, J P89*, P120, P161 Esposito, R P34, P125, P273,

P300 Esser, S P41*, P76* Estany, C P150 Estrada, V P54 Etzel, A P4 Everhard, F P306, P309 Evers, S P163

Fabbiani, M P243* Fakoya, A PCH Falco, V P40 Fang, W P240 Fantoni, M P99 Farajallah, A P8, P61, P63 Fardel, V P231 Farrell, G P276 Fätkenheuer, G O425, P12,

P157*, P195, P266 Fernandez, S P112 Ferramosca, S P39 Ferreira, A P296 Ferreira, D P296 Ferrer, E P44, P53, P92 Ferrer, M P114, P171, P176 Ferrer, P P54, P78 FHDH-ANRS 04, the P299 Filice, C P119 Firlag-Burkacka, E P184 Fisher, M O332, O422 Fituri, OA P214 Flaherty, J P61, P63 Flamm, J P157 Flandre, P P26 Fleming, C P199 Florence, E P36*, P37, P228*,

P270*, P283 Flores, J P64 Floyd, S P11 Foggia, M P3 Fomundam, H P73 Fontas, E O314 Forbici, F P179 Force, L P92 Fortuny, C P143, P144 Fox, R O31CH, P103, P219,

P225, P253*, P291 Fox, S P68 Fox, Z P183 Francisci, D P10, P84*, P118 Francque, S P270, P283 Fraser, C P277 Fredrick, L P110 Freedberg, K O113 Friedland, G O411*, P240

Friend-du Preez, N P73 Friis-Møller, N O313, O314 Fumaz, C P114, P171*, P176* Furrer, H O412 Fusetti, G P45

Gagliani, L P196, P209 Gaikwad, S P193 Galani, L P294 Galindo, M P134 Gallagher, L P277 Gallego, M P102 Galli, L P45, P202 Galli, M P1, P39, P119, P194,

P274 Gallo, C P290 Gallo, L P12, P76 Garb, J O214 Garcia, M P33, P58 García, P P146 García Benaya, E P93, P100 García Lacalle, C P93, P100 Garcia-Alcalde, M P134 García-Bujalance, L P314 García-García, J P164, P254 García-Henarejos, J P42, P44, P164, P254 García-Samaniego, J P268,

P284 Gargalianos, P P124, P186 Garrabou, G P142*, P143,

P144, P146* Garraffo, R P26 Garren, K P312 Garrido, C P20 Garrido, M P134 Garvey, L P301* Gascon, J P288 Gaspar, G P173, P251* Gatell, J O332, O42CH, SS4CH,

P53* Gathercole, L P113 Gatti, F P52*, P267, P282 Gazzard, B SS2CH, SS2.1, PCH,

P14, P16, P49, P116, P129, P151, P248 Geijo, P P42, P92, P134 Genoway, K P277 Georgoulakis, J P294 Geretti, AM SS4.3 Germano, I P96 Gersbacher, E P195 Gervasoni, C P119 G-Franco, A P290 Ghaji, N P149 Ghanem, M P15 Giamarellou, H P124, P294 Giancola, M P166, P169 Gianelli, E P74

Giannaris, M P124 Gianotti, N P3, P45 Giaquinto, C O222 Gibb, D O122, O125, O222* Gibbons, S O121, P199, P233,

P246 Gibbs, S P110 Gibellini, D P123 Giffo, B P29 Gilks, C O125 Gilliam, B P121 Ginocchio, F P215 Giola, M P234* Girardi, E O412 Gisolf, E P55, P60 Giubelan, L P257 Giulianelli, M P169 Giuntini, R P74 Gizinska, J P258 Goelz, J P195 Gogos, H P124 Goikoetxea, J P33 Goldbach, J P41 Golegã, A P209 Gölz, J P76 Gómez-Sirvent, J P221 Gómez-Sucerquia, L P161 Gonzalez, A P130, P302 González, M P221 González, Y P161 Gonzalez-García, J P264 González-Lahoz, J P20, P128,

P137 Gonzalez-Mena, A P64 González-Mestre, V P114 González-Pardo, G P66 Goodrich, J O425, P154 Gorèíková, J P212 Gori, A P97, P167 Gori, C P35 Gorowara, M P244 Graf, B P16* Grana, M P102, P112 Grancea, C P182 Granholm, H P82 Granier, C P83 Grant, D P110 Grebely, J P277 Green, H O112, O222 Gregis, G O213 Greil, R P200 Griffa, L P80, P117*, P264 Grima, P P106, P131 Grima, PF P106*, P131* Grimm, K P63 Grinsztejn, B P21, P24 Grisaru, G P188 Groeneveld, P P55 Grossi, P P234

(19)

AUTHOR INDEX (continued)

Grosskurth, H P11 Grosso, C P74 Grulich, A O321* Guaraldi, G P34*, P94*, P115,

P125*, P139*, P140*, P156, P177, P300* Guatelli, K P196 Guelar, A P130, P302* Guevara, F P20 Guiget, M P269 Gulick, R O425, CS2.1, CS2CH Gulizia, R P119* Gupta, A P16 Gupta, N P158 Gupte, N P193 Gussio, M P17 Gute, P P18, P32 Gutierrez, F P53 Gutierrez, M P67 Gyllensten, K P82*

Haas, B P83 Habel, A O214 Haberl, A P32, P71*, P76 Haigney, Z O413 Hain, J P86* Haine, D P81 Hairrell, J P110 Hakim, J O132* Hamlyn, E P260 Hamouda, O O423 Han, D P197 Hanhoff, N P71 Hankins, C CoS.1 Hanna, G P185 Hanzlíková, J P212 Hardy, WD O425* Harris, M P271 Harrison, L O112 Hartkoorn, R P238 Hartmans, N P208 Harxhi, A P87* Hassoun, G P188 Hatz, C CS1.5 Hatzakis, A P47, P186 Haubrich, R P27*, P312 Hay, P P6, P250 Heera, J O425 Hegener, P P135, P160 Hemmett, L P313 Henke, J P135, P160 Hennessy, M P91, P236 Hepburn, M P219, P225 Hernandez-Quero, J P42, P64 Herrero-Segastume, V P164,

P254 Hertling, S P62 Hervás, R P173 Hervey, C P207

Hill, A P5*, P36, P37, P127, P178, P181 Hirschel, B CoS.2, ES2.1 HIV/TB Study Group O412 Hjelmgren, J P313 Hodder, S P63* Hoepelman, A P60 Hoepelman, I P55 Hoetelmans, R P239 Höhn, C P43 Høj, L O313, P183 Hojman, M P227* Holas, C P95 Holm, S P71 Holmes, P P14, P248 Holodniy, M P9 Horban, A PCH, P184 Hornberger, J P318 Hosein, S CoSCH Hosseina, M P277 Hristea, A P255 Huang, W P197 Hughes, P P11 Huitema, A P242 Hull, M P271* Husstedt, I P163* Hutt, E P306*, P309*

Iacoviello, L P99 Iannotti, N P99 Ibrahim, F P262 Idris El Ammari, I P214 Ilie, M P226 Imaz, A P40* Ionescu, C P275 Iosipenco, M P255 Iribarren, J P33, P221, P314 Isaacs, R P207 Isenman, H P248 Ive, P O124, P2 Iwuala, S P126* Izopet, J P26

Jackson, A P276 Jackson, AGA P129, P151 Jackson, F P83 Jackson, V P199*, P246 Jadhav, S P211* Jaegel-Guedes, E P195 Jaeger, H P7, P13, P25, P41,

P75, P195 Jaffe, H O224* Jan, E P91 Janke, M P266 Jansen, K P272 Jarrin, I P279 Jauer, M P200 Jayasuriya, A P249

Jensen, J O214 Jimenez, I P268 Jiménez-Nácher, I P66 Johnson, M O333, O21CH, P6,

P23, P83, P250 Judd, A O122 Jullien, V P287 Jusdado, J P251 Jusdado Ruiz-Capillas, J P93,

P100

Kabeya, K P48 Kachman, E P188 Kaiser, R P201 Kakuda, T O413*, P272 Kalath, T P257 Kambraki, M P214 Kanjavanit, S O222 Karafoulidou, A P47, P186 Karaiskos, I P294 Karakitsos, P P294 Kasteren, M P55 Katabira, E O131* Katlama, C KL2*, SS2.3, ES2.4,

P21*, P22*, P26, P38, P269, P272 Katsarolis, I P294 Kavatha, D P294 Kawiya, J O125 Kedem, E P188 Kelleher, A P297 Kelly, S P132* Kerndt, P P303 Kerr, S P244 Kestens, D P239 Khanna, M P158 Khatib, N P49 Khaykin, P P32, P122 Khoo, S O121*, O123*, O125,

PCH, P6, P199, P233, P237, P238, P241, P246, P250 Kiely, B P293 Kieran, J P246, P276* Kigen, G O121 Kim, D P247 Kimaiyo, S O121 Kinder, F O214 Kint, I P223*, P228 Kirk, O O212, O313, O332,

O412 Kirschner, J P147, P148 Kiss, L P197 Kitas, G SS3.3 Kittikraisak, W P259 Kityo, C O125* Kjær, J P183* Klauke, S P12, P18, P32, P59 Klein, C P95*, P101, P245, P247

Name Activity Name Activity Name Activity

(20)

Knecht, G P13, P25, P59, P122 Knechten, H P12, P13*, P25,

P43*, P195 Knight, E P277 Knobel, H P53, P130, P302 Koegl, C P75* Koeppe, S P25 Kok, P P263 Kollan, C O423 Komninakis, S P196, P209 Konig, J P295 Konopnicki, D P289* Kontos, A P85 Koole, O P228 Koopmans, P P55 Körber, A P76 Kordossis, T P85*, P186 Kourkoudi, S P124 Kovacs, C P81 Kowalska, J O313* Kraemer, S P29 Kraja, D P87 Kreuzberg, C O423 Krivine, A P46 Ktorza, N P38 Kumar, R P72, P310 Kumarasamy, N P72, P111 Kumari, B P15 Kuritzkes, D O115* Kurowski, M P59 Kwan, W P238

La Rosa, R P17 Labarga, P P128*, P137, P265,

P268 Lacombe, K O212 Lafuente-Lafuente, C P279 Laird, J P291 Lalezari, J O413 Lallemant, M O222 Lambert, J P109, P199, P246* Lampe, F O333 Lampreia, F P96 Lane, HC KL2* Larrouse, M P54 Larson, J P197 Lascoux-Combe, C P299 Lataillade, M P180*, P185 Latarska-Smuga, D P258 Laterreur, J P298 Lathouwers, E O424 Lattanzi, A P94 Lattimore, S O112 Lauriola, M P206 Laursen, T P174 Law, M O314 Lazanas, MC P47, P105, P186 Lazanas, ML P124

Lázaro, P P308 Lazzarin, A O415, P21, P45,

P76, P202, P272 Lazzaroni, L P234 Lebrecht, D P145, P147, P148 Ledergerber, B O212, O331 Lee, A P203 Lee, V P79 Leen, C P315 Lefebvre, E P157 Lefevre, V P222 Legrand, J P55 Lekander, I P315* Leleu, G O415 Lennemann, T P122 Leoncini, L P69 Letang, E CS1.3, P288* Levy, Y SS1.3 Leyes, M P221 Li, J P101 Libertone, R P292 Lim, P P72 Limb, S P203 Lin, S P240 Lin, Y P101 Lins-Filho, A P209 Lisv

ka, M P212 Liuzzi, G P292* Llibre, J P42*, P50, P58, P191 Lo Caputo, S P35*, P206 Lo Cicero, M P39 Lobo, J P290* Loeschel, E P83 Logue, K P81 Lonardo, A P139, P140 Longo, N P81 Lopardo, G P317 López, R P65 López-Aldeguer, J P134, P221 Lopez-Bernaldo de Quiros, J

P64 López-Blánquez, R P142 López Gomez, M P44 Lorenzini, P P3, P169, P179 Loria, P P139, P140 Losina, E O113 Losso, M O414 Loutfy, M P318 Loy, A CS1.1 Loyo, K P124 Lozano, F P134 Luechters, G P266 Luminos, M P255 Lundgren, J O212, O312*,

O313, O314, O331, O332, O412, P183 Lutwana, F O125 Lutz, T P12, P13, P25, P59, P122

Lyall, H O122, O223*, O222, O22CH Lynen, L P283 Lyons, F P293

Maa, J P8, P61, P63 MacConnachie, A P103, P219,

P225, P253, P291 Machala, L O331, P295 Macias, J P141* Mackie, K P204 Mackintosh, C P253 MacPherson, P CoS.3 MacRae, K P297 Mactier, H P219, P225 Madeddu, G P19, P74 Madejon, A P284 Madruga, J P4* Maes, P P223 Magafas, N P124 Magenta, A P153 Maggiolo, F O213*, P3, P167* Magiorkinis, E P47, P186 Magiorkinis, G P47, P186 Magnier, J P279 Mahungu, T P238 Mahungu, TW P6*, P250 Maida, I P138*, P286 Mair, R P229 Majluf Cruz, A P104, P108 Makne, A P193 Malashenkov, E O412 Maldonado, M P227 Malincarne, L P10* Mallal, S PCH Mallolas, J P53 Mallon, P O322*, SS6.4 Mallon, PW P70 Maltez, F P51 Manata, M P51 Mancini, M P136, P180 Manconi, P P133 Mandalia, S P129, P151 Manfredi, R P165* Mangafas, N P105 Manigart, Y P289 Manolescu, L P182* Manonelles, G P227 Mansinho, K P51 Manzini, L P273 Manzoli, L P19 Marasca, G P168 Marcas, C P226 Marcelin, A P178 Marchetti, G P1, P88*, P97 Marconi, P P74, P166, P179 Marcotullio, S PCH Marczyñska, M O222, P216, P217*

Imagem

Referências